Key facts
- Affinity Asset Advisors, LLC filed SCHEDULE 13G/A for Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value per share (KPTI).
- Disclosed ownership: 8.6%.
- Date of event: 31 Mar 2026.
Affinity Asset Advisors, LLC - 31 Mar 2026 SCHEDULE 13G/A Report for Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value per share (KPTI)
- Filing Manager
- Affinity Asset Advisors, LLC
- Reporting Manager
- Affinity Asset Advisors, LLC
- Symbol
- KPTI
- Shares outstanding
- 24,110,663 shares
- Disclosed Ownership
- 2,073,517 shares
- Ownership
- 8.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 May 2026, 16:05:54 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Key filing fact
Affinity Asset Advisors, LLC disclosed 8.6% ownership in Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value per share (KPTI) on 31 Mar 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 May 2026, 16:05.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 8.6% | 2,073,517 | 2,073,517 | 0 | /s/ Andrew Weinstein | Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer | |
| Michael Cho | 8.6% | 2,073,517 | 2,073,517 | 0 | /s/ Michael Cho | Michael Cho, Self |
CIK / CUSIP context first